Real-world Study of Lenalidomide After First-line Treatment Lenvatinib With PD-1 in Advanced HCC

Summary

This study is a real-world, single-arm, observational study primarily collecting data on patients with hepatocellular carcinoma who experienced disease progression after receiving lenvatinib in combination with PD-1 inhibitors as part of routine clinical practice, and evaluating the efficacy of adding lenalidomide to their treatment regimen.

Timeline

Start

2023-05-24

Primary completion

2025-04-30

Completion

2025-04-30

Drugs

Indications